JP2013516454A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013516454A5 JP2013516454A5 JP2012547585A JP2012547585A JP2013516454A5 JP 2013516454 A5 JP2013516454 A5 JP 2013516454A5 JP 2012547585 A JP2012547585 A JP 2012547585A JP 2012547585 A JP2012547585 A JP 2012547585A JP 2013516454 A5 JP2013516454 A5 JP 2013516454A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- administration
- adenoviral vector
- sequence shown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28222810P | 2010-01-05 | 2010-01-05 | |
| US61/282,228 | 2010-01-05 | ||
| US28224710P | 2010-01-07 | 2010-01-07 | |
| US61/282,247 | 2010-01-07 | ||
| PCT/IL2011/000007 WO2011083464A2 (en) | 2010-01-05 | 2011-01-05 | Methods for use of a specific anti-angiogenic adenoviral agent |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017085788A Division JP2017186341A (ja) | 2010-01-05 | 2017-04-25 | 特異的な抗血管形成アデノウイルス剤の使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013516454A JP2013516454A (ja) | 2013-05-13 |
| JP2013516454A5 true JP2013516454A5 (enExample) | 2014-02-20 |
| JP6196040B2 JP6196040B2 (ja) | 2017-09-13 |
Family
ID=44305892
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012547585A Expired - Fee Related JP6196040B2 (ja) | 2010-01-05 | 2011-01-05 | 特異的な抗血管形成アデノウイルス剤の使用法 |
| JP2017085788A Pending JP2017186341A (ja) | 2010-01-05 | 2017-04-25 | 特異的な抗血管形成アデノウイルス剤の使用法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017085788A Pending JP2017186341A (ja) | 2010-01-05 | 2017-04-25 | 特異的な抗血管形成アデノウイルス剤の使用法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9567605B2 (enExample) |
| EP (2) | EP3159405B8 (enExample) |
| JP (2) | JP6196040B2 (enExample) |
| KR (1) | KR101754437B1 (enExample) |
| AU (1) | AU2011204405B2 (enExample) |
| CA (1) | CA2786374C (enExample) |
| DK (2) | DK3159405T3 (enExample) |
| MX (1) | MX342641B (enExample) |
| NZ (1) | NZ601324A (enExample) |
| SG (2) | SG182367A1 (enExample) |
| WO (1) | WO2011083464A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003222427B8 (en) | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| US8071740B2 (en) * | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| KR100866117B1 (ko) | 2001-10-19 | 2008-10-31 | 바스큘라 바이오제닉스 리미티드 | 혈관형성의 표적화 억제조절 및 항암 치료를 위한폴리뉴클레오타이드 작제물, 약학적 조성물 및 방법 |
| CA2658972C (en) | 2006-07-31 | 2019-11-26 | Vascular Biogenics Ltd. | Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia |
| EP2521777B1 (en) | 2010-01-05 | 2016-12-28 | Vascular Biogenics Ltd. | Compositions and methods for treating glioblastoma gbm |
| NZ601324A (en) | 2010-01-05 | 2014-10-31 | Vascular Biogenics Ltd | Methods for use of a specific anti-angiogenic adenoviral agent |
| KR102229084B1 (ko) | 2012-10-17 | 2021-03-18 | 바스큘라 바이오제닉스 리미티드 | 아데노바이러스를 사용하는 치료 방법 |
| US9511046B2 (en) * | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| WO2014118643A2 (en) | 2013-02-04 | 2014-08-07 | Vascular Biogenics Ltd. | Methods of inducing responsiveness to anti-angiogenic agent |
| US9771385B2 (en) | 2014-11-26 | 2017-09-26 | Vascular Biogenics Ltd. | Oxidized lipids |
| CN106999506A (zh) | 2014-11-26 | 2017-08-01 | 脉管生物生长有限公司 | 氧化脂质以及纤维化的治疗或预防 |
| CN111356480A (zh) | 2017-10-20 | 2020-06-30 | 脉管生物生长有限公司 | 用于抗血管生成剂疗法的诊断方法 |
| US10525127B2 (en) * | 2018-03-31 | 2020-01-07 | Femtomab | P14.7 protein and uses thereof as vaccine adjuvant |
| CA3103367A1 (en) * | 2018-06-13 | 2019-12-19 | The Council Of The Queensland Institute Of Medical Research | Viral detection assay |
| US20220154212A1 (en) * | 2019-03-13 | 2022-05-19 | Vascular Biogenics Ltd. | Methods of anti-tumor therapy |
| BR112021020225A2 (pt) | 2019-04-12 | 2021-12-07 | Vascular Biogenics Ltd | Métodos de terapia antitumoral |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US5747340A (en) | 1994-06-03 | 1998-05-05 | Syntex (U.S.A.) Inc. | Targeted gene expression using preproendothelin-1 promoters |
| US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| JP4492826B2 (ja) | 1996-11-20 | 2010-06-30 | イントロジェン セラピューティクス，インコーポレイテッド | アデノウイルスベクターの産生および精製のための改良された方法 |
| US6204055B1 (en) | 1999-04-12 | 2001-03-20 | Isis Pharmaceuticals, Inc. | Antisense inhibition of Fas mediated signaling |
| US7691370B2 (en) | 1998-10-15 | 2010-04-06 | Canji, Inc. | Selectivity replicating viral vector |
| US6649158B1 (en) | 1998-10-15 | 2003-11-18 | Canji, Inc. | Methods and compositions to induce antitumor response |
| EP1185627A2 (en) | 1999-06-01 | 2002-03-13 | Cornell Research Foundation, Inc. | Activation of dendritic cells to enhance immunity |
| IL130608A0 (en) | 1999-06-23 | 2000-06-01 | Compugen Ltd | Novel nucleic and amino acid sequence |
| US6867022B1 (en) * | 2000-01-21 | 2005-03-15 | Regents Of The University Of Michigan | Replication deficient adenovirus vectors and methods of making and using them |
| US8039261B2 (en) | 2000-11-17 | 2011-10-18 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| CA2429342C (en) | 2000-11-17 | 2013-03-19 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| US20070286845A1 (en) * | 2000-11-17 | 2007-12-13 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| US20100282634A1 (en) | 2000-11-17 | 2010-11-11 | Dror Harats | Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis |
| US8071740B2 (en) | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| AU2003222427B8 (en) | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| US7067649B2 (en) | 2000-11-17 | 2006-06-27 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| KR100866117B1 (ko) | 2001-10-19 | 2008-10-31 | 바스큘라 바이오제닉스 리미티드 | 혈관형성의 표적화 억제조절 및 항암 치료를 위한폴리뉴클레오타이드 작제물, 약학적 조성물 및 방법 |
| CA2511665A1 (en) * | 2002-12-18 | 2004-07-01 | Novartis Ag | Endothelial cell specifically binding peptides |
| US20080293652A1 (en) | 2004-02-24 | 2008-11-27 | Introgen Therapeutics, Inc. | Combination of Ad-P53 and Chemotherapy for the Treatment of Tumours |
| EP1786904A4 (en) | 2004-08-09 | 2010-06-16 | Merck Sharp & Dohme | Adenovirus vector COMPOSITIONS |
| WO2006079176A1 (en) | 2005-01-28 | 2006-08-03 | Apollo Life Sciences Limited | Molecules and chimeric molecules thereof |
| CN101360499B (zh) * | 2005-10-06 | 2015-10-07 | 默沙东公司 | 吡唑并[1,5-a]嘧啶衍生物在制备抑制蛋白激酶的药物中的用途 |
| CA2658972C (en) | 2006-07-31 | 2019-11-26 | Vascular Biogenics Ltd. | Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia |
| NZ601324A (en) | 2010-01-05 | 2014-10-31 | Vascular Biogenics Ltd | Methods for use of a specific anti-angiogenic adenoviral agent |
| EP2521777B1 (en) | 2010-01-05 | 2016-12-28 | Vascular Biogenics Ltd. | Compositions and methods for treating glioblastoma gbm |
| JP6009357B2 (ja) | 2010-01-12 | 2016-10-19 | バスキュラー バイオジェニックス リミテッド | アデノウイルスベクターの生産方法およびそれによって生成されるウイルス調製物 |
| KR102229084B1 (ko) | 2012-10-17 | 2021-03-18 | 바스큘라 바이오제닉스 리미티드 | 아데노바이러스를 사용하는 치료 방법 |
-
2011
- 2011-01-05 NZ NZ601324A patent/NZ601324A/en not_active IP Right Cessation
- 2011-01-05 WO PCT/IL2011/000007 patent/WO2011083464A2/en not_active Ceased
- 2011-01-05 MX MX2012007849A patent/MX342641B/es active IP Right Grant
- 2011-01-05 US US13/520,457 patent/US9567605B2/en not_active Expired - Fee Related
- 2011-01-05 SG SG2012049581A patent/SG182367A1/en unknown
- 2011-01-05 CA CA2786374A patent/CA2786374C/en active Active
- 2011-01-05 EP EP16196233.7A patent/EP3159405B8/en active Active
- 2011-01-05 SG SG10201500013SA patent/SG10201500013SA/en unknown
- 2011-01-05 AU AU2011204405A patent/AU2011204405B2/en not_active Ceased
- 2011-01-05 DK DK16196233.7T patent/DK3159405T3/en active
- 2011-01-05 DK DK11731733.9T patent/DK2521776T3/en active
- 2011-01-05 KR KR1020127020566A patent/KR101754437B1/ko not_active Expired - Fee Related
- 2011-01-05 JP JP2012547585A patent/JP6196040B2/ja not_active Expired - Fee Related
- 2011-01-05 EP EP11731733.9A patent/EP2521776B1/en active Active
-
2013
- 2013-03-12 US US13/797,160 patent/US20130280217A1/en not_active Abandoned
- 2013-03-12 US US13/796,991 patent/US20130280216A1/en not_active Abandoned
-
2017
- 2017-04-25 JP JP2017085788A patent/JP2017186341A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013516454A5 (enExample) | ||
| Di et al. | Combined adjuvant of poly I: C improves antitumor effects of CAR-T cells | |
| Bartee et al. | Tumor-localized secretion of soluble PD1 enhances oncolytic virotherapy | |
| Fang et al. | Emerging nano-/biotechnology drives oncolytic virus-activated and combined cancer immunotherapy | |
| Longo et al. | Immunotherapeutic approaches for hepatocellular carcinoma | |
| JP2021063120A5 (enExample) | ||
| JP7146739B2 (ja) | 癌を処置するためのアデノウイルスとチェックポイント阻害剤の組合せ | |
| US12576131B2 (en) | Altering inflammatory states of immune cells in vivo by modulating cellular activation states | |
| JP2008507536A5 (enExample) | ||
| JP2016538885A5 (enExample) | ||
| JP2013189456A5 (enExample) | ||
| JP2016533753A5 (enExample) | ||
| JP2019506862A5 (enExample) | ||
| Castillo-Rodriguez et al. | Suicide HSVtk gene delivery by neurotensin-polyplex nanoparticles via the bloodstream and GCV Treatment specifically inhibit the growth of human MDA-MB-231 triple negative breast cancer tumors xenografted in athymic mice | |
| WO2014198852A2 (en) | A dosing regime and formulations for type b adenoviruses | |
| Thoidingjam et al. | Oncolytic virus-based suicide gene therapy for cancer treatment: A perspective of the clinical trials conducted at Henry Ford Health | |
| Zhu et al. | Recent advances in oncolytic virus therapy for hepatocellular carcinoma | |
| Gonzalez-Aseguinolaza et al. | Gene therapy of liver diseases: a 2011 perspective | |
| JP2011503039A5 (enExample) | ||
| Zhou et al. | An update on the clinical trial research of immunotherapy for glioblastoma | |
| Hu et al. | Nanomaterial manipulation of immune microenvironment in the diseased liver | |
| Parrasia et al. | Targeting pancreatic ductal adenocarcinoma (PDAC) | |
| Snyder et al. | Good CARMA: Turning bad tumor‐resident myeloid cells good with chimeric antigen receptor macrophages | |
| Warricker et al. | The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma | |
| TW202309077A (zh) | 用於治療實性瘤的靶向ｃｄ７０的基因工程化免疫細胞 |